Q-omics provides the consensus-scored LYPD4 profile across patient tissues and cancer cell-line models. LYPD4 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LYPD4 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, LYPD4 RNA expression shows 6,683 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where LYPD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYPD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYPD4 survival associations across molecular data types. LYPD4 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYPD4 RNA expression–survival associations across cancer types. High LYPD4 expression shows unfavorable associations in KIRC, KICH, UCS, CHOL and TGCT, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LYPD4 RNA expression.
This table summarizes LYPD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LYPD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYPD4 shows higher tumor expression in BRCA, UCEC, ESCA, KIRP, LUAD and CHOL. The BRCA box plot shows higher LYPD4 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .007).
This table shows molecular features associated with LYPD4 in patient tissues and cancer cell lines. In patient samples, LYPD4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LYPD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
